Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 9 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Enzalutamide (Xtandi) for non-metastatic prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2017	View \| Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy	Enzalutamide (Xtandi; MDV3100)	Non-metastatic prostate cancer	Male Reproductive Cancer	2022	View \| Download
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Pembrolizumab with Enzalutamide and androgen deprivation therapy for the treatment of metastatic hormone sensitive prostate cancer	Androgen deprivation therapy , Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Pembrolizumab with enzalutamide for treating metastatic castration-resistant prostate cancer	Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer	Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Talazoparib with enzalutamide for previously untreated homologous recombination repair-mutated metastatic hormonal-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate)	Prostate cancer	Male Reproductive Cancer	2024	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications